Lan W-G, Hao Y-Z, Xu D-H, Wang P, Zhou Y-L, Ma L-B
Department of Oncology, Binzhou Medical University Hospital, Binzhou, China.
Department of Infectious Diseases, Binzhou Medical University Hospital, Binzhou, China.
Clin Transl Oncol. 2016 Apr;18(4):375-80. doi: 10.1007/s12094-015-1375-y. Epub 2015 Sep 2.
To investigate the role of human epididymis protein 4 (HE4) in the diagnosis and prognosis of patients with locally advanced non-small cell lung cancer (LA-NSCLC) receiving concurrent chemoradiotherapy (CRT).
A total of 218 patients with LA-NSCLC were enrolled. All patients underwent CRT. The treatment response to CRT was evaluated. The prognosis analysis was performed using relapse-free survival (RFS) and overall survival [1].
Our data show that the serum HE4 can discriminate patients who respond well to CRT from those who respond poorly. Higher serum HE4 had dramatically increased risk of being non-responders to CRT. Serum HE4 level is also associated with prognosis of patients after CRT. Patients with high HE4 level had shorter RFS and OS compared to those with low HE4 level.
Our data suggest that serum HE4 may be a useful prognostic biomarker for LA-NSCLC patients who underwent CRT.
探讨人附睾蛋白4（HE4）在接受同步放化疗（CRT）的局部晚期非小细胞肺癌（LA-NSCLC）患者的诊断及预后中的作用。
共纳入218例LA-NSCLC患者。所有患者均接受CRT。评估CRT的治疗反应。采用无复发生存期（RFS）和总生存期进行预后分析[1]。
我们的数据表明，血清HE4能够区分对CRT反应良好的患者和反应较差的患者。血清HE4水平较高显著增加了对CRT无反应者的风险。血清HE4水平也与CRT后患者的预后相关。与低HE4水平的患者相比，高HE4水平的患者RFS和OS更短。
我们的数据表明，血清HE4可能是接受CRT的LA-NSCLC患者有用的预后生物标志物。
